increases in cardiac hypertrophy were significantly smaller in MAFbx KO than in WT mice. There was significantly less lung congestion and interstitial fibrosis in MAFbx KO than in WT mice. MAFbx KO also inhibited ␤-adrenergic cardiac hypertrophy. DNA microarray analysis revealed that activation of genes associated with the transcription factor binding site for the nuclear factor-B family were inhibited in MAFbx KO mice compared with WT mice after TAC. Although the levels of IB-␣ were significantly decreased after TAC in WT mice, they were increased in MAFbx KO mice. MAFbx regulates ubiquitination and proteasomal degradation of IB-␣ in cardiomyocytes. In primary cultured rat cardiomyocytes, phenylephrine-induced activation of nuclear factor-B and hypertrophy were significantly suppressed by MAFbx knockdown but were partially rescued by overexpression of nuclear factor-B p65. 
critical mediator of skeletal muscle atrophy. 8, 9 Because protein degradation is promoted under conditions of cardiac atrophy and regression of cardiac hypertrophy, 10 it was originally postulated that MAFbx may mediate atrophy or regression of hypertrophy in cardiac muscle as well. However, thus far, the role of endogenous MAFbx in mediating regression of cardiac hypertrophy has not been clearly demonstrated. Interestingly, a study conducted with MAFbx knockout (KO) mice showed that endogenous MAFbx negatively regulates cardiac hypertrophy in response to exercise, 11 a model of physiological hypertrophy. In contrast, the role of MAFbx in regulating pathological hypertrophy has been studied only with a gain-of-function animal model in vivo, in which overexpressed MAFbx inhibited PO-induced hypertrophy by targeting calcineurin for ubiquitin-mediated proteolysis. 12 Thus, the role of endogenous MAFbx in the heart during pathological hypertrophy and failure remains to be studied with a loss-of-function animal model. Cardiac hypertrophy caused by pathological insults is accompanied by increases in protein synthesis and ER stress, which require protein quality control mediated by the UPS. 5 However, the role of the UPS in left ventricular hypertrophy and remodeling is controversial. 13 Thus, testing whether MAFbx is involved in pathological hypertrophy is important.
We investigated the role of MAFbx in mediating a pathological form of cardiac hypertrophy. We asked (1) whether endogenous MAFbx is upregulated during hypertrophy induced by PO, (2) whether endogenous MAFbx positively or negatively mediates cardiac hypertrophy induced by PO, and (3) which downstream target mediates the effect of MAFbx on pathological hypertrophy. Surprisingly, our study, using a loss-of-function mouse model, allowed us to identify a novel function of MAFbx, namely to critically mediate but not inhibit PO-induced cardiac hypertrophy.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Mice
MAFbx KO mice have been described 9 (Novartis Institutes for Biomedical Research). All experiments involving animals were approved by the Institutional Animal Care and Use Committee at the New Jersey Medical School.
Adenoviral Vectors
Adenovirus harboring rat MAFbx and recombinant adenovirus vector containing the hairpin-forming oligo were constructed, amplified, and titered as described. 14 The hairpin-forming oligo of sh-MAFbx corresponds to bases 474 to 494 of the rat MAFbx gene.
Statistics
All values are expressed as meanϮSEM except where noted. Statistical analyses were performed by either t test or ANOVA and the Tukey posttest procedure, with PϽ0.05 considered significant.
Results

MAFbx Plays an Important Role in Mediating PO-Induced Cardiac Hypertrophy
We examined the effect of PO on expression of MAFbx in the mouse heart. Although protein and mRNA expression of MAFbx is low under basal conditions, it was significantly upregulated 1 week after transverse aortic constriction (TAC) and further increased at 2 weeks ( Figure 1A ). Phosphorylation of FoxO3a, a transcription factor known to upregulate MAFbx, was increased after TAC, which presumably induces nuclear exit of FoxO3a, suggesting that TAC-induced upregulation of MAFbx may be mediated by FoxO3a-independent mechanisms. To examine the role of the MAFbx upregulation in mediating PO-induced cardiac hypertrophy, we applied TAC to MAFbx KO and wild-type (WT) mice. After 2 weeks, the pressure gradient was not significantly different between MAFbx KO and WT mice (Online Figure IA , Online Table I ). Interestingly, TAC-induced increases in LV weight/body weight and LV weight/tibial length were significantly attenuated in MAFbx KO mice compared with that in WT mice ( Figure 1B , Online Figure  IB , and Online Table II) , as were TAC-induced increases in echocardiographically determined LV wall thickness (Online Figure IC and Online Table III) . TAC-induced increases in LV myocyte cross-sectional area were also significantly attenuated in MAFbx KO mice ( Figure 1C ). These results suggest that the lack of MAFbx attenuates PO-induced cardiac hypertrophy. We also examined the role of MAFbx in mediating hypertrophy induced by phenylephrine (PE), an ␣1-adrenergic receptor agonist, in cultured cardiomyocytes. Downregulation of MAFbx by adenovirus harboring shRNA-MAFbx significantly attenuated PE-induced cardiac hypertrophy ( Figure 1D ), suggesting that MAFbx plays an essential role in mediating hypertrophy at the myocyte level.
Lack of MAFbx Inhibits PO-Induced Cardiac Dysfunction
We examined the effect of MAFbx KO on cardiac function after TAC for 2 and 4 weeks. The increase in lung weight/ body weight, an indicator of lung congestion, after TAC was significantly attenuated in MAFbx KO compared with WT mice at 2 weeks (Online Table II ) and 4 weeks ( Figure 2A and Online Table IV ). Echocardiographic measurements showed that decreases in LV ejection fraction and percent fractional shortening after TAC were significantly attenuated in MAFbx KO mice at 4 weeks ( Figure 2BCD and Online Table  IV ). Hemodynamic measurement showed that an increase in LV end-diastolic pressure after TAC was abolished in MAFbx KO mice at 2 weeks (Online Table I ) and 4 weeks ( Figure 2E ). Taken together, these data show that decreases in LV function and the development of heart failure after PO were significantly attenuated in MAFbx KO mice, suggesting that upregulation of MAFbx during PO not only stimulates hypertrophy but also induces LV dysfunction and heart failure.
Non-standard Abbreviations and Acronyms
Lack of MAFbx Inhibits PO-Induced Cardiac Remodeling
TAC-induced hypertrophy was accompanied by upregulation of fetal type genes, including atrial natriuretic factor and ␣-skeletal actin, in WT mice. TAC-induced upregulation of the fetal type genes was significantly attenuated in MAFbx KO mice ( Figure 3A and 3B). The ratio of mRNA expression of ␤-MHC/␣-MHC was significantly increased after TAC in WT mice. TAC-induced upregulation of this ratio was significantly attenuated in MAFbx KO mice ( Figure 3C ), suggesting that genetic ablation of MAFbx inhibits PO-induced fetal gene expression. Histological analyses showed that TAC-induced increases in interstitial fibrosis were significantly attenuated in MAFbx KO mice ( Figure 3D ). The number of TUNEL and troponin T double-positive nuclei was increased in both WT and MAFbx KO mice after TAC compared with respective sham-operated mice. However, the increase in the percentage of the double-positive nuclei was significantly smaller in MAFbx KO than in WT mice ( Figure  3E ). Thus, the cardiac phenotype commonly observed in pathological hypertrophy was significantly attenuated in MAFbx KO mice compared with WT mice. To examine whether endogenous MAFbx also plays an important role in mediating cardiac hypertrophy in response to another stimulus, WT and MAFbx KO mice were subjected to continuous infusion of isoproterenol, an agonist for the ␤-adrenergic receptor, for 2 weeks. The heart rate and mean blood pressure after isoproterenol infusion were not significantly Figure II2F) , myocyte cross-sectional area, and fibrosis (Online Figure IIIA , B) in the heart were attenuated in MAFbx KO hearts. These results suggest that MAFbx also plays an important role in mediating ␤-adrenergic cardiac hypertrophy and cardiac dysfunction in vivo.
Deletion of MAFbx Normalizes Changes in the Gene Expression Profile Induced by PO
To further characterize the effect of MAFbx KO on phenotypic changes in the heart in response to TAC in an unbiased manner, a DNA microarray analysis was conducted, using total RNA prepared from WT and MAFbx KO mouse hearts subjected to TAC. To examine the effect of MAFbx KO on TAC-induced changes in gene expression, we plotted the relationship between changes induced by TAC in the WT heart and changes induced by MAFbx KO in hearts subjected to TAC for all genes. The graph shows that TAC-induced changes in gene expression in WT for each gene (x-axis in Figure 4A ) inversely correlated with differences in gene expression after TAC between MAFbx KO and WT (y-axis in Figure 4A ), indicating attenuation of gene regulation in MAFbx KO in response to TAC. Transcription factor binding site analysis was conducted with the use of microarray data. The results of the transcription factor binding site analysis suggested that genes with binding sites for the nuclear factor (NF)-B family of transcription factors in the promoter region were significantly downregulated in MAFbx KO mice (Online Table V and Figure 4B ). TAC-induced upregulation of the genes with binding sites for the NF-B family of transcription factors in the promoter region, including interleukin (IL)-6, Bcl-3, and Tnfrsf1b, was significantly attenuated in MAFbx KO mice compared with WT mice (Online Table VI and Figure 4C ). To further investigate whether the binding of NF-B to the target genes is regulated by MAFbx, we performed a chromatin immunoprecipitation (ChIP) assay in heart homogenates obtained from WT or MAFbx-KO mice, using antibody against NF-B-p65. The ChIP product was subjected to polymerase chain reaction with a pair of primers designed to amplify the fragment of the IL-6 gene promoter region containing the NF-B-binding motif ( Figure 4D top 3 panels and Online Figure  IV) . A pair of primers designed to amplify the fragment of the IL-6 gene promoter region that does not contain the NF-Bbinding motif were used as a negative control ( Figure 4D , lower 2 panels). The results showed that NF-B binds to the IL-6 promoter and PO enhances the DNA binding of NF-B in WT mice. However, the TAC-induced enhancement of the NF-B binding to the IL-6 promoter was significantly attenuated in MAFbx KO mice. Collectively, these results suggest that MAFbx facilitates DNA binding of NF-B and expression of the NF-B target genes in the heart in response to PO.
Downregulation of MAFbx Inhibits Activation of NF-B by Hypertrophic Stimuli
To examine whether MAFbx KO affects NF-B-mediated transcription, we examined expression of NF-B by immunostaining. Although expression of NF-B is low in shamoperated mouse hearts, TAC significantly increased NF-B nuclear staining in WT hearts. In contrast, TAC-induced increases in NF-B nuclear staining were significantly attenuated in MAFbx KO hearts ( Figure 5A and Online Figure V) . Consistently, although protein expression of IB-␣, an inhibitor of NF-B, was significantly decreased after TAC in WT hearts, it was significantly increased in sham-operated MAFbx KO hearts and was further enhanced after TAC in the MAFbx KO hearts ( Figure 5B ). Phosphorylation of IB-␣ was significantly increased after TAC in WT hearts, consistent with the decrease in IB-␣ in response to TAC. In MAFbx KO mice, the level of phosphorylated IB-␣ was significantly increased in sham-operated hearts and it was further increased after TAC, indicating that IB-␣ is stabilized even in the presence of phosphorylation. MAFbx KO did not significantly affect the level of total IB kinase-␣ (IKK-␣) or phosphorylated IKK/total IKK after sham and TAC ( Figure 5B ) mRNA expression of IB-␣ was increased significantly after TAC in both WT and MAFbx KO hearts, but there was no significant difference between WT and MAFbx KO hearts ( Figure 5C ). PE-induced upregulation of NF-B in the nucleus was also attenuated in the presence of shRNA-MAFbx in cultured cardiomyocytes ( Figure 5D ). In addition, PE-induced increases in the transcriptional activity of NF-B, as evaluated by reporter gene assays, were attenuated in the presence of shRNA-MAFbx ( Figure 5E ). These results suggest that endogenous MAFbx plays an essential role in mediating upregulation of NF-B-mediated transcription by hypertrophic stimuli in cardiomyocytes and that these effects of MAFbx are cell-autonomous in cardiomyocytes.
Because IB-␣ is accumulated in the absence of endogenous MAFbx, we hypothesized that proteasome degradation of IB-␣ is regulated by MAFbx. Coimmunoprecipitation assays indicated that myc-MAFbx and IB␣ physically associate with one another in cardiomyocytes in vitro ( Figure 6A ). To test whether MAFbx directly ubiquitinates IB, in vitro ubiquitination assays were performed with recombinant proteins. glutathione S transferase-MAFbx and cdc34, an E2 ubiquitin-conjugating enzyme, were incubated with biotinubiquitin, a ubiquitin-activating enzyme (E1), and glutathione S transferase-IB-␣, and the reaction mixture was subjected to immunoblotting with anti-ubiquitin and anti-IB-␣ antibodies. Ubiquitination of IB, as assessed by the detection of high-molecular-weight polyubiquitin chains of ubiquitin and monoubiquitinated IB-␣, was detected in a reaction containing E1, cdc34, MAFbx, and ubiquitin ( Figure 6B ). Deletion of any single component in this reaction abolished ubiquitination of IB-␣. The extent of IB-␣ ubiquitination was evaluated with the use of the glutathione S transferasetandem ubiquitin-binding entity assay. 15 Although the total amount of ubiquitin-conjugated proteins was similar among the samples analyzed, the level of ubiquitinated IB-␣ after TAC was significantly greater in the WT mouse heart than in the MAFbx KO heart ( Figure 6C ). Overexpression of MAFbx decreased expression of IB-␣ in cardiomyocytes, an effect that was reversed in the presence of MG132, a proteasome inhibitor ( Figure 6D ). These results suggest that MAFbx induces destabilization of IB-␣ through ubiquitination and proteasomal degradation. To test whether accumulation of ⌱〉-␣ and downregulation of NF-B play an important role in mediating the suppression of cardiac hypertrophy in MAFbx knockdown myocytes, a rescue experiment was conducted. Overexpression of p65, one of the NF-B subunits, in the presence of MAFbx knockdown, partially restored expression of p65 and attenuated the inhibition of PE-induced cardiomyocyte hypertrophy by MAFbx downregulation ( Figure 6E ). These results suggest that the lack of MAFbx attenuates PE-induced cardiac hypertrophy in part through downregulation of the NF-B pathway. Interestingly, overexpression of MAFbx also inhibited PE-induced cardiomyocyte hypertrophy. Overexpression of MAFbx markedly enhanced PE-induced accumulation of p65, suggesting that exogenous MAFbx appears to inhibit cardiac hypertrophy through IB-NF-B-independent mechanisms.
Discussion
Our results suggest that endogenous MAFbx/atrogin-1 plays a key role in mediating the development of pathological hypertrophy. Expression of MAFbx is increased in response to PO, and hypertrophy induced by either PO or ␤-adrenergic stimulation is significantly inhibited in MAFbx KO mice. Furthermore, downregulation of MAFbx inhibits LV dysfunction in response to PO and ␤-adrenergic stimulation. These findings are in contrast with the role of MAFbx in skeletal muscle, where MAFbx mediates denervation-induced atrophy, 9 as well as with the inhibitory role of MAFbx in exercise-induced cardiac hypertrophy in the heart. 11 We propose that MAFbx mediates pathological hypertrophy in part through proteasomal degradation of IB-␣ and stabilization of NF-B.
MAFbx is strongly upregulated by PO in the heart at both the mRNA and protein levels. MAFbx was originally identified as a gene upregulated when skeletal muscle undergoes denervationinduced atrophy. 11 However, mRNA expression of fetal-type genes and genes encoding the UPS are generally upregulated in the heart during both hypertrophy and atrophy. 16 In cardiomyocytes, both FoxO3a 17 and tumor necrosis factor-␣ 18 upregulate expression of MAFbx, whereas Akt 19 and exercise 19 reduce it. FoxO3a induces atrophy of the heart. 17 Because FoxO3a is phosphorylated and presumably excluded from the nucleus by PO, it is unlikely that FoxO3a mediates upregulation of MAFbx in our TAC model. The level of tumor necrosis factor-␣ is increased by PO and in the failing heart, and tumor necrosis factor-␣ could stimulate hypertrophy. 20 Thus, it will be interesting to elucidate the role of tumor necrosis factor-␣ in mediating upregulation of MAFbx in response to PO.
Our results suggest that upregulation of MAFbx during PO positively mediates hypertrophy and cardiac dysfunction. To our knowledge, the role of MAFbx in mediating pathological hypertrophy has not been investigated with a loss-of-function mouse model. The fact that the lack of MAFbx reverses the changes in the gene expression profile that accompany PO-induced hypertrophy, as evaluated by unbiased DNA microarray analyses, confirms the reversal of the hypertrophy phenotype in the MAFbx KO mice, supporting our hypothesis. Because selective knockdown of MAFbx also inhibited PE-induced cardiac hypertrophy in cardiomyocytes in vitro, the role of MAFbx in mediating cardiac hypertrophy must be cell-autonomous.
It should be noted that Li et al 12 reported that overexpression of MAFbx in the heart inhibits TAC-induced cardiac hypertrophy. Overexpressed MAFbx directly binds to calcineurin and promotes its degradation. Because calcineurin plays an important role in mediating cardiac hypertrophy, the authors proposed that overexpression of MAFbx may inhibit cardiac hypertrophy through suppression of calcineurin. 21 These results are in marked contrast with our finding that MAFbx mediates cardiac hypertrophy in response to PO. Furthermore, upregulation of calcineurin in response to PO was significantly inhibited in MAFbx KO mice in our hands (Online Figure VI) . This difference may be due to the fact that Li et al used a gain-of-function model, 12 whereas we used a loss-of-function model of MAFbx. In fact, we found that overexpression of MAFbx partially inhibited PE-induced hypertrophy in cultured cardiomyocytes despite marked accumulation of p65-NF-B. This raises a possibility that exogenously overexpressed MAFbx regulates additional targets, thereby inhibiting cardiac hypertrophy. Although expression of MAFbx is low at baseline, it is markedly increased by PO. The loss-of-function model would be more useful for evaluating the role of endogenous MAFbx upregulation in regulating hypertrophy during PO. Li et al also demonstrated that MAFbx negatively regulates physiological hypertrophy, using MAFbx KO mice. 11 Previous studies showed that several molecules, such as Akt 22 and ASK, 23 not only promote physiological hypertrophy but also suppress pathological hypertrophy. Thus, it is possible that the role of MAFbx in suppression of physiological hypertrophy and mediation of PO-induced hypertrophy may involve a common mechanism. At present, however, this hypothesis remains to be tested.
In the present report, we show that MAFbx regulates pathological hypertrophy in part through activation of the NF-B pathway. Transcription factor binding site analyses showed that genes with DNA-binding sites for the NF-B family were significantly downregulated compared with genes without NF-B binding sites. Subsequent analyses showed that ubiquitination of IB-␣, a negative regulator of NF-B, in the PO heart was significantly attenuated in MAFbx KO mice. Furthermore, MAFbx and IB-␣ physically interact with one another, and MAFbx induces proteasomal degradation of IB-␣. MAFbx directly uniquitinates IkB in vitro. Although further investigation is needed to prove that IB-␣ is a direct and physiological substrate of MAFbx in the heart in vivo, these results suggest that endogenous MAFbx regulates UPS-induced degradation of IB-␣ in cardiomyocytes.
Pharmacological blockade of NF-〉 activation with pyrrolidine dithiocarbamate inhibits cardiac hypertrophy and cardiac remodeling. 24 Additionally, cardiac-specific NF-B inhibition by expression of a stabilized IB-␣ mutant attenuates angiotensin II-induced hypertrophy. 25 Furthermore, the targeted disruption of the p50 subunit of NF-B has been shown to attenuate myocardial hypertrophy. 26 These findings suggest that NF-B plays an important role in the development of cardiac hypertrophy as well as cardiac dysfunction. It should be noted that the heart weight and cardiomyocyte size in MAFbx KO mice are not significantly different from those in WT mice at baseline, despite significant accumulation of IB-␣. We speculate that other mechanisms override the MAFbx-NF-B pathway to prevent baseline hypertrophy. NF-B is one of the most important signaling pathways linked to the loss of skeletal muscle mass during aging, disuse, space travel, AIDS, sepsis, cancer, and chronic heart failure. 27 This dichotomic function of NF-B in cardiac and skeletal muscle may partially explain why MAFbx KO attenuates pathological hypertrophy in cardiac muscles but attenuates atrophy in skeletal muscle.
Although the complete suppression of PE-induced cardiac hypertrophy in the presence of MAFbx knockdown was reversed when NF-B was overexpressed, the reversal was partial. We speculate that MAFbx may regulate additional molecules to mediate cardiac hypertrophy. Recent evidence suggests that MAFbx regulates expression of MPK-1, a phosphatase, thereby inducing persistent activation of JNKs and apoptosis of cardiomyocytes. 28 We have shown previously, however, that activation of the MEKK1-JNK pathway during PO negatively regulates cardiac hypertrophy and cardiac dysfunction. 29 Thus, the role of the MPK1-JNK pathway in mediating the effect of MAFbx during PO remains to be elucidated.
Our findings have significant clinical implications. First, endogenous MAFbx not only mediates hypertrophy but also induces cardiac dysfunction during PO. Second, expression of MAFbx is increased in skeletal muscle in chronic heart failure. 30 MAFbx is implicated in the development of muscle atrophy during cardiac cachexia. 30 We therefore speculate that intervention to attenuate the function of MAFbx during cardiac hypertrophy and heart failure may not only ameliorate cardiac remodeling and dysfunction but also prevent skeletal muscle atrophy, a significant complication in patients with heart failure.
In conclusion, endogenous MAFbx plays an essential role in mediating pathological cardiac hypertrophy in response to PO, in part through nuclear accumulation of NF-B (Online Figure VII) . We propose that MAFbx and its downstream signaling molecules, including NF-B, could be important targets for future treatment of patients with heart failure.
The ubiquitin proteasome system (UPS) is a major mechanism of protein degradation, thereby contributing to protein homeostasis, protein quality control, and intracellular signaling mechanisms. E3 ligases serve as an interface between signaling mechanisms and the UPS, thereby controlling the levels of specific intracellular proteins under stress. MAFbx/atrogin-1 is a muscle-specific E3 ubiquitin ligase that plays an important role in regulating muscle mass in conditions, such as skeletal atrophy and cardiac hypertrophy. Previous studies, using a gain-of-function mouse model, have shown that overexpressed MAFbx attenuates cardiac hypertrophy. However, the involvement of endogenous MAFbx in pathological hypertrophy was unknown. With the use of a loss-of-function mouse model, we demonstrate that endogenous MAFbx plays an essential role in mediating pressure overload-induced cardiac hypertrophy and heart failure through UPS degradation of IB and consequent stabilization of nuclear factor-B. Thus, our results provide a novel example of an E3 ligase that can induce pathological hypertrophy through UPS-mediated regulation of hypertrophysignaling mechanisms. Furthermore, because both MAFbx and nuclear factor-B facilitate skeletal muscle atrophy, which is a significant complication in patients with heart failure, our results suggest that MAFbx could be an important target for heart failure treatment.
